temozolomide has been researched along with Cytomegalic Inclusion Disease in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 7.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 7.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 5.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma." | 4.86 | Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010) |
| " Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses." | 3.91 | Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report. ( Bloch, O; Grimm, SA; Horbinski, CM; Kumthekar, PU; Lamano, JB; Quaggin-Smith, JA; Tate, MC, 2019) |
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 3.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 3.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 1.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "We report the case of a patient with primary brain tumor who developed cytomegalovirus associated colonic pseudotumor as an opportunistic infection while receiving chemotherapy with Temozolomide and radiation." | 1.35 | Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. ( De Jesus, A; Grossman, SA; Paun, O, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, P | 1 |
| Neumann, DM | 1 |
| Weathers, SP | 1 |
| Penas-Prado, M | 1 |
| Pei, BL | 1 |
| Ling, X | 1 |
| Kassab, C | 1 |
| Banerjee, P | 1 |
| Bdiwi, M | 1 |
| Shaim, H | 1 |
| Alsuliman, A | 1 |
| Shanley, M | 1 |
| de Groot, JF | 1 |
| O'Brien, BJ | 1 |
| Harrison, R | 1 |
| Majd, N | 1 |
| Kamiya-Matsuoka, C | 1 |
| Fuller, GN | 1 |
| Huse, JT | 1 |
| Chi, L | 1 |
| Rao, G | 1 |
| Weinberg, JS | 1 |
| Lang, FF | 1 |
| Sawaya, R | 1 |
| Shpall, EJ | 1 |
| Rezvani, K | 1 |
| Heimberger, AB | 2 |
| Furukawa, R | 1 |
| Homma, H | 1 |
| Inoue, T | 1 |
| Horiuchi, H | 1 |
| Usui, K | 1 |
| Lamano, JB | 1 |
| Quaggin-Smith, JA | 1 |
| Horbinski, CM | 1 |
| Tate, MC | 1 |
| Grimm, SA | 1 |
| Kumthekar, PU | 1 |
| Bloch, O | 1 |
| Ferguson, SD | 1 |
| Srinivasan, VM | 1 |
| Ghali, MG | 1 |
| Yaman, E | 1 |
| Coskun, U | 1 |
| Ozturk, B | 1 |
| Buyukberber, S | 1 |
| Kaya, AO | 1 |
| Coskun, O | 1 |
| Buyukberber, N | 1 |
| Yildiz, R | 1 |
| Benekli, M | 1 |
| De Jesus, A | 1 |
| Grossman, SA | 1 |
| Paun, O | 1 |
| Gousias, K | 1 |
| Konstantinos, G | 1 |
| Kyritsis, A | 1 |
| Athanasios, K | 1 |
| Meije, Y | 1 |
| Lizasoain, M | 1 |
| García-Reyne, A | 1 |
| Martínez, P | 1 |
| Rodríguez, V | 1 |
| López-Medrano, F | 1 |
| Juan, RS | 1 |
| Lalueza, A | 1 |
| Aguado, JM | 1 |
| Okita, Y | 1 |
| Narita, Y | 1 |
| Miyakita, Y | 1 |
| Ohno, M | 1 |
| Nagai, S | 1 |
| Shibui, S | 1 |
| Schwarzberg, AB | 1 |
| Stover, EH | 1 |
| Sengupta, T | 1 |
| Michelini, A | 1 |
| Vincitore, M | 1 |
| Baden, LR | 1 |
| Kulke, MH | 1 |
2 reviews available for temozolomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Hu | 2016 |
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infection | 2010 |
1 trial available for temozolomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Topics: Adult; CD8-Positive T-Lymphocytes; Cytomegalovirus; Cytomegalovirus Infections; Female; Glioblastoma | 2020 |
8 other studies available for temozolomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Persistent HCMV infection of a glioblastoma cell line contributes to the development of resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytomegalovi | 2020 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Colitis; Cytomegalovirus Infections; Female; Glioblastoma; | 2019 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F | 2009 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; | 2012 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |